Abbott Laboratories - Global Healthcare Leader in Diagnostics, Medical Devices, Nutrition, and Pharm

📢 Key Milestones (2025-2026):
   Abbott reported $44.328 billion in net sales for FY2025. On March 23, 2026, the company completed the $21 billion acquisition of Exact Sciences, expected to add approximately $3 billion in incremental sales for 2026. Q1 2026 revenue reached $11.164 billion (+7.8% YoY) with adjusted EPS of $1.15. Full-year 2026 guidance projects comparAble sales growth of 6.5%-7.5% and adjusted EPS of $5.38-$5.58. The quarterly dividend was increased to $0.63 per share (April 2026).

Company Overview (Updated April 2026)

Abbott Laboratories (NYSE: ABT) is a global healthcare company dedicated to helping people live fully at all stages of life. Headquartered in Abbott Park, Illinois, the company discovers, develops, manufactures, and sells a diversified line of healthcare products across four reportable segments: Diagnostic Products, Medical Devices, Nutritional Products, and Established Pharmaceutical Products.

Founded in 1888 by Dr. Wallace C. Abbott, the company has grown into one of the world's largest and most diversified healthcare enterprises, serving people in more than 160 countries with approximately 114,000 employees worldwide. Abbott is recognized as one of Fortune's "Most Admired Companies" and maintains a robust innovation pipeline with significant investments in R&D.

Corporate History

- 1888: Founded by Dr. Wallace C. Abbott in Chicago as a small pharmaceutical practice

- 1929: Listed on the New York Stock Exchange

- 1964: Introduced the first diagnostic test for hepatitis

- 1985: Developed the first HIV blood test, revolutionizing blood screening

- 2013: Separated into two independent publicly traded companies—Abbott (diversified medical products) and AbbVie (research-based pharmaceuticals)

- 2017: Acquired St. Jude Medical ($25 billion) and Alere ($5.3 billion), significantly expanding cardiovascular and diagnostics capabilities

- 2024: Announced agreement to acquire test preparation assets from Luminex

- March 23, 2026: Completed acquisition of Exact Sciences for approximately $21 billion, bolstering diagnostics portfolio in cancer screening and precision oncology

Business Segments

Diagnostic Products

Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. Includes Core Laboratory, Rapid Diagnostics, Molecular, and Point of Care businesses.

Key Products: Alinity integrated diagnostic systems, i-STAT handheld blood analyzers, ID NOW molecular platform, FreeStyle Libre glucose monitoring systems

Medical Devices

Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, Neuromodulation, and diabetes care products.

Key Products: FreeStyle Libre CGM systems, MitraClip structural heart repair, Amplatzer occluders, electrophysiology mapping and ablation systems, vascular stents and guidewires

Nutritional Products

Worldwide sales of adult and pediatric nutritional products, including Similac, Ensure, Pedialyte, and Glucerna brands.

Note: The company has faced ongoing litigation related to necrotizing enterocolitis (NEC) in premature infants using cow's milk-based formulas. In April 2026, a Chicago jury issued a $53 million verdict against Abbott.

Established Pharmaceutical Products

International sales of branded generic pharmaceutical products across emerging markets, focusing on gastroenterology, women's health, cardiovascular, pain management, and respiratory therapies.

Financial Performance

FY 2025 Results

- Net Sales: $44.328 billion (vs. $41.950 billion in 2024, +5.7%)

- U.S. Sales: $17.126 billion

- International Sales: $27.202 billion

- Net Earnings: $6.524 billion

- Diluted EPS: $3.72

- Operating Cash Flow: $9.566 billion

- Capital Expenditures: $2.171 billion

- Total Assets: $86.713 billion

- Shareholders' Investment: $52.771 billion

- Long-term Debt: $12.929 billion

- R&D Expenses: $2.942 billion

- Gross Profit Margin: 52.6%

- Cash Dividends Declared: $2.40 per share

Q1 2026 Results (April 16, 2026)

- Net Sales: $11.164 billion (+7.8% YoY)

- GAAP Net Earnings: $1.077 billion

- GAAP Diluted EPS: $0.61

- Adjusted Net Earnings: $2.022 billion (excluding specified items)

- Adjusted Diluted EPS: $1.15 (vs. analyst consensus $1.16)

- Medical Devices Growth: +8.5% (led by cardiovascular devices)

- Diagnostics Sales: +2% (core lab growth offset by 10% decline in rapid/molecular due to lower respiratory testing)

- EPD Sales: +9% (broad market growth)

2026 Financial Guidance

- Comparable Sales Growth: 6.5% to 7.5%

- Adjusted EPS: $5.38 to $5.58 (revised from prior $5.55-$5.80 due to ~$0.20 dilution from Exact Sciences acquisition)

- Q2 2026 Adjusted EPS: $1.25 to $1.31

- Exact Sciences Contribution: Expected to add approximately $3 billion in sales for full-year 2026

Leadership

Robert B. Ford: Chairman of the Board and Chief Executive Officer

Phil Boudreau: Executive Vice President, Finance and Chief Financial Officer

Mary K. Moreland: Executive Vice President

Daniel Gesua Sive Salvadori: Executive Vice President and Group President

Louis H. Morrone: Executive Vice President

Eric Shroff: Senior Vice President

Elizabeth C. Cushman: Executive Vice President, General Counsel and Secretary

Major 2026 Developments

Exact Sciences Acquisition (March 23, 2026): Abbott completed the approximately $21 billion acquisition of Exact Sciences, a leader in cancer screening and precision oncology. The acquisition strengthens Abbott's diagnostics portfolio with Cologuard (non-invasive colorectal cancer screening) and Oncotype DX (genomic breast cancer tests), expected to contribute ~$3 billion in 2026 sales.

Product Line Realignment (January 1, 2026): The Amplatzer Amulet Left Atrial Appendage Occluder and related accessories were transferred from the Structural Heart business to the Electrophysiology business.

Dividend Increase (April 2026): Quarterly dividend of $0.63 per share, reflecting Abbott's 53Rd consecutive year of dividend increases and its position as a Dividend King.

Investor Response: Despite Q1 revenue beat, shares declined following the guidance revision related to Exact Sciences dilution, though the stock had risen 28.4% over the preceding 52 weeks.

Corporate Information

Legal Name: Abbott Laboratories

- Founded: 1888

- Headquarters: 100 Abbott Park Road, Abbott Park, IL 60064, USA

- Stock Ticker: ABT (NYSE)

- Employees: Approximately 114,000

- Countries Served: 160+

- Website: www.abbott.com

- Investor Relations: www.abbottinvestor.com

Contact Information

Corporate Headquarters:
   100 Abbott Park Road
   Abbott Park, IL 60064
   United States

Media: +1 (224) 668-3224

Investor Relations: +1 (224) 668-3222

Keywords: Abbott Laboratories, ABT, NYSE, Robert Ford, Phil Boudreau, Abbott Park Illinois, diagnostics, medical devices, nutrition, established pharmaceuticals, FreeStyle Libre, Alinity, Exact Sciences acquisition 2026, Cologuard, Oncotype DX, Q1 2026 earnings, $44.328 billion revenue, 1888, global healthcare, Dividend King, Dividend Aristocrat, St. Jude Medical, Alere